HEARTCARE-B (06609) surged more than 13% again, bringing its total post-earnings gains to over 40%. At the time of writing, the stock was up 8.24% to HK$59.1, with a turnover of HK$13.44 million. The company recently released its annual results, reporting full-year revenue of 408 million yuan, a 46.9% year-on-year increase. Concurrently, the company maintained a gross profit margin above 70%, achieving a net profit of 83.34 million yuan, marking a significant turnaround from a loss to a profit compared to the previous year. This signals that the company's strategic layout in the neurointervention field is entering a harvest phase. Notably, the company plans to submit an application for an A-share listing on the STAR Market in 2026. Management outlined several development targets during the earnings conference: maintaining an annualized revenue growth of no less than 35% over the next three years, and striving to become the market share leader among domestic neurointervention brands by 2028. Regarding overseas revenue, the company expects it to contribute over 10% by 2028, exceeding 100 million yuan in scale. On the profit front, the company aims to achieve a net profit margin of approximately 20%, with the gross profit margin expected to stabilize between 68% and 70%, ensuring stable profitability through refined expense management and economies of scale.